Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLC005
MIFTS: 57

Placental Insufficiency

Categories: Blood diseases, Cardiovascular diseases, Fetal diseases, Rare diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Placental Insufficiency

About this section

MalaCards integrated aliases for Placental Insufficiency:

Name: Placental Insufficiency 12 58 54 43 15 17 71
Uteroplacental Vascular Insufficiency 58

Characteristics:

Orphanet epidemiological data:

58
placental insufficiency
Inheritance: Not applicable; Prevalence: 1-5/10000 (Worldwide); Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Fetal diseases
Anatomical: Reproductive diseases Cardiovascular diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:3891
MeSH 43 D010927
SNOMED-CT 67 237292005
ICD10 via Orphanet 33 O36.5
UMLS via Orphanet 72 C0032051
Orphanet 58 ORPHA439167
UMLS 71 C0032051
Sources

Summaries for Placental Insufficiency

About this section
Disease Ontology : 12 A placenta disease that is characterized by insufficient blood flow to the placenta during pregnancy.

MalaCards based summary : Placental Insufficiency, also known as uteroplacental vascular insufficiency, is related to antiphospholipid syndrome and funisitis. An important gene associated with Placental Insufficiency is PGF (Placental Growth Factor), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Enoxaparin and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include placenta, heart and brain, and related phenotypes are intrauterine growth retardation and hypoxemia

Wikipedia : 74 Placental insufficiency or utero-placental insufficiency is the failure of the placenta to deliver... more...

Sources

Related Diseases for Placental Insufficiency

About this section

Diseases related to Placental Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 332)
# Related Disease Score Top Affiliating Genes
1 antiphospholipid syndrome 32.9 SERPINC1 PGF F3 F2
2 funisitis 30.7 IL6 CXCL8 ANGPT1
3 eclampsia 30.7 VEGFA SERPINC1 PGF PAPPA IL6 FLT1
4 triploidy 30.5 PAPPA AFP
5 oligohydramnios 30.4 PGF PAPPA FGR AFP
6 chorioangioma 30.4 ANGPT1 AFP
7 severe pre-eclampsia 30.3 VEGFA SERPINC1 PGF PAPPA LEP HIF1A
8 tricuspid valve insufficiency 30.3 PAPPA F3 F2
9 pyelonephritis 30.3 PGF IL6 CXCL8
10 chorioamnionitis 30.2 VEGFA IL6 FLT1 CXCL8
11 twin-to-twin transfusion syndrome 30.1 PGF PAPPA FLT1 ANGPT2 ANGPT1
12 cerebral palsy 30.0 SERPINC1 LEP IL6 F2 CXCL8
13 placental abruption 30.0 SERPINC1 PGF PAPPA FLT1 F2
14 hellp syndrome 29.6 VEGFA SERPINC1 PGF LEP IL6 FLT1
15 vascular disease 29.4 VEGFA TEK SERPINC1 LEP KDR IL6
16 pre-eclampsia 29.3 VEGFA SERPINC1 PGF PAPPA LEP KDR
17 placenta disease 28.7 VEGFA SERPINC1 PGF PAPPA MIR520A IL6
18 hypertension, essential 27.2 VEGFA TH TEK SERPINC1 PGF PAPPA
19 cholestasis, intrahepatic, of pregnancy, 1 11.3
20 cholestasis, intrahepatic, of pregnancy 3 11.3
21 intravascular papillary endothelial hyperplasia 10.6 VEGFA HIF1A
22 septate uterus 10.6 KDR FLT1
23 microcystic meningioma 10.6 VEGFA FLT1
24 cancer-associated retinopathy 10.6 VEGFA PGF FLT1
25 obesity-hypoventilation syndrome 10.6 LEP IL6
26 achenbach syndrome 10.6 F3 F2
27 angiokeratoma of mibelli 10.6 KDR FLT1
28 chromosomal triplication 10.6 PAPPA AFP
29 intermediate malignant teratoma 10.6 PAPPA AFP
30 neonatal anemia 10.6 PGF PAPPA FLT1
31 glomeruloid hemangioma 10.6 VEGFA IL6 FLT1
32 peripartum cardiomyopathy 10.6 VEGFA PGF FLT1
33 acute mountain sickness 10.6 VEGFA HIF1A FLT1
34 hypertensive encephalopathy 10.6 VEGFA FLT1 F2
35 synovial angioma 10.6 F3 F2
36 hematocele of tunica vaginalis testis 10.6 F2 AFP
37 patau syndrome 10.5 PGF PAPPA AFP
38 renal pelvis squamous cell carcinoma 10.5 F3 F2
39 immature teratoma of ovary 10.5 F2 AFP
40 vascular cancer 10.5 VEGFA KDR FLT1
41 idiopathic anterior uveitis 10.5 IL6 CXCL8
42 emphysematous cholecystitis 10.5 F3 F2
43 primary cutaneous b-cell lymphoma 10.5 VEGFA KDR FLT1
44 non-gestational ovarian choriocarcinoma 10.5 TEK AFP
45 angiodysplasia 10.5 VEGFA F3 ANGPT2
46 spinal cord infarction 10.5 SERPINC1 F2
47 femoral neuropathy 10.5 F3 F2
48 lung non-squamous non-small cell carcinoma 10.5 VEGFA KDR FLT1
49 gastroesophageal junction adenocarcinoma 10.5 VEGFA KDR FLT1
50 papillary adenofibroma 10.5 F3 F2 AFP

Graphical network of the top 20 diseases related to Placental Insufficiency:



Diseases related to Placental Insufficiency
Sources

Symptoms & Phenotypes for Placental Insufficiency

About this section

Human phenotypes related to Placental Insufficiency:

58 31 (show all 20)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 intrauterine growth retardation 58 31 hallmark (90%) Very frequent (99-80%) HP:0001511
2 hypoxemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0012418
3 small for gestational age 58 31 hallmark (90%) Very frequent (99-80%) HP:0001518
4 proportionate short stature 58 31 hallmark (90%) Very frequent (99-80%) HP:0003508
5 small placenta 58 31 hallmark (90%) Very frequent (99-80%) HP:0006266
6 abnormal umbilical cord blood vessels 58 31 hallmark (90%) Very frequent (99-80%) HP:0011403
7 autism 58 31 frequent (33%) Frequent (79-30%) HP:0000717
8 antiphospholipid antibody positivity 58 31 frequent (33%) Frequent (79-30%) HP:0003613
9 systemic lupus erythematosus 58 31 frequent (33%) Frequent (79-30%) HP:0002725
10 neurodevelopmental abnormality 58 31 frequent (33%) Frequent (79-30%) HP:0012759
11 abnormal lung morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0002088
12 cerebral palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0100021
13 abnormal heart morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0001627
14 insulin resistance 58 31 occasional (7.5%) Occasional (29-5%) HP:0000855
15 spontaneous abortion 58 31 occasional (7.5%) Occasional (29-5%) HP:0005268
16 preeclampsia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100602
17 eclampsia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100601
18 maternal hypertension 58 31 occasional (7.5%) Occasional (29-5%) HP:0008071
19 autistic behavior 58 Frequent (79-30%)
20 abnormality of the placenta 58 Obligate (100%)

GenomeRNAi Phenotypes related to Placental Insufficiency according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-109 9.44 PAPPA
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-13 9.44 F3
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-132 9.44 FLT1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.44 F3
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 9.44 PAPPA
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.44 FLT1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.44 FLT1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.44 PAPPA
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 9.44 FLT1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-32 9.44 PAPPA
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-6 9.44 PAPPA
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-78 9.44 F3
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-8 9.44 PAPPA

MGI Mouse Phenotypes related to Placental Insufficiency:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.48 ANGPT1 ANGPT2 F2 F3 FGR FLT1
2 homeostasis/metabolism MP:0005376 10.42 AFP ANGPT1 ANGPT2 F2 F3 FLT1
3 growth/size/body region MP:0005378 10.37 ANGPT1 F2 F3 FLT1 HIF1A IL6
4 immune system MP:0005387 10.32 ANGPT1 ANGPT2 F2 F3 FGR FLT1
5 embryo MP:0005380 10.31 ANGPT1 F2 F3 FLT1 HIF1A KDR
6 hematopoietic system MP:0005397 10.29 F2 F3 FGR FLT1 HIF1A IL6
7 mortality/aging MP:0010768 10.28 AFP ANGPT1 ANGPT2 F2 F3 FLT1
8 integument MP:0010771 10.23 ANGPT2 F2 F3 FGR HIF1A IL6
9 liver/biliary system MP:0005370 10.09 AFP HIF1A IL6 KDR LEP SERPINC1
10 nervous system MP:0003631 10.03 ANGPT1 F2 F3 FLT1 HIF1A IL6
11 muscle MP:0005369 10.02 ANGPT1 F3 FLT1 HIF1A IL6 KDR
12 neoplasm MP:0002006 9.92 AFP F3 HIF1A IL6 LEP PGF
13 normal MP:0002873 9.9 F2 F3 FGR FLT1 HIF1A KDR
14 respiratory system MP:0005388 9.7 ANGPT2 F2 F3 HIF1A IL6 KDR
15 vision/eye MP:0005391 9.44 ANGPT1 ANGPT2 F3 FLT1 HIF1A IL6
Sources

Drugs & Therapeutics for Placental Insufficiency

About this section

Drugs for Placental Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Enoxaparin Approved Phase 4 9005-49-6 772
2
tannic acid Approved Phase 4 1401-55-4
3
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
4
Dinoprostone Approved Phase 4 363-24-6 5280360
5
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
6
Dalteparin Approved Phase 3 9005-49-6
7
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
8
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
9 Heparin, Low-Molecular-Weight Phase 3
10 Phosphodiesterase 5 Inhibitors Phase 2, Phase 3
11 Phosphodiesterase Inhibitors Phase 2, Phase 3
12 Citrate Phase 2, Phase 3
13 Vasodilator Agents Phase 2, Phase 3
14 Sildenafil Citrate Phase 2, Phase 3 171599-83-0
15
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
16
Heparin Approved, Investigational Phase 2 9005-49-6 46507594 772
17
Certolizumab pegol Approved Phase 2 428863-50-7
18 Fibrinolytic Agents Phase 2
19 Analgesics, Non-Narcotic Phase 2
20 Cyclooxygenase Inhibitors Phase 2
21 Platelet Aggregation Inhibitors Phase 2
22 Analgesics Phase 2
23 Antipyretics Phase 2
24 Anti-Inflammatory Agents Phase 2
25 Anti-Inflammatory Agents, Non-Steroidal Phase 2
26 Antirheumatic Agents Phase 2
27 calcium heparin Phase 2
28 Immunologic Factors Phase 2
29 Immunosuppressive Agents Phase 2
30
Allopurinol Approved 315-30-0 2094
31 Coconut Approved
32
Ondansetron Approved 99614-02-5 4595
33
Hydroxyurea Approved 127-07-1 3657
34
Iron Approved, Experimental 15438-31-0, 7439-89-6 27284 23925
35
Vitamin A Approved, Nutraceutical, Vet_approved 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
36
Pomegranate Experimental, Investigational
37 Protective Agents
38 Antimetabolites
39 Angiogenesis Inhibitors
40 Angiogenesis Inducing Agents
41 Anesthetics
42 Retinol palmitate
43 retinol
44 Pharmaceutical Solutions
45 Fibrin fragment D
46 Antiemetics
47 Anticoagulants
48 Lupus Coagulation Inhibitor
49 Antibodies, Antiphospholipid
50 Antioxidants

Interventional clinical trials:

(show top 50) (show all 51)
# Name Status NCT ID Phase Drugs
1 Enoxaparine en PREvention Des insuffiSAnces Placentaires Chez Les Femmes eNCEintes Completed NCT03528967 Phase 4 Enoxaparin 40 mg / 0.4 mL Prefilled Syringe;Aspirin 100 mg Oral Tablet, Enteric Coated
2 Evaluation of Dose-response Effect of Acetylsalicylic Acid on Placental Development, Preterm Birth, Fetal Growth and Hypertension in Pregnancy in Women With Previous History of Preeclampsia Completed NCT01352234 Phase 4 Acetylsalicylic Acid 160 mg;Acetylsalicylic Acid 80 mg
3 A Prospective Multi-centre Randomised Comparison on Induction of Labour With Double-balloon Installation Device Versus Prostaglandin E2 Minprostin Completed NCT01255839 Phase 4 Minprostin
4 Pilot Double-Blind Placebo Controlled Trial of Levothyroxine in Pregnant Systemic Lupus Erythematosus (SLE) Patients With Autoimmune Thyroid Disease Withdrawn NCT01276782 Phase 4 Levothyroxine
5 Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction Treatment Unknown status NCT03230162 Phase 3 Sildenafil;low molecular weight heparin
6 Enoxaparin for the Prevention of Placental‐Mediated Complications of Pregnancy in Women With Obstetric History or Abnormal Uterine Artery Doppler at First Trimester Ultrasound and Without Thrombophilia: a Multicenter Randomized Controlled Trial Completed NCT01388322 Phase 3 Enoxaparin
7 A Randomized Controlled Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction Completed NCT02590536 Phase 3 Sildenafil citrate;placebo
8 The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction) Terminated NCT02277132 Phase 2, Phase 3 Sildenafil;Placebo
9 Sildenafil Citrate for the Management of Asymmetrical Intrauterine Growth Restriction Unknown status NCT02678221 Phase 2 Sildenafil citrate;Aspirin
10 Aspirin for the Enhancement of Trophoblastic Invasion in Women With Abnormal Uterine Artery Doppler at 11-14 Weeks of Gestation Completed NCT01616615 Phase 2 Aspirin;placebo
11 Certolizumab to Prevent Pregnancy Complications in High-Risk Patients With APS or SLE - (IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy) Recruiting NCT03152058 Phase 2 Certolizumab Pegol
12 Does Antenatal Allopurinol Administration Improve Maternal and Neonatal Outcome in Intrauterine Growth Restriction? Unknown status NCT00346463 Allopurinol
13 Revealed Versus Concealed Criteria for Placental Insufficiency in Unselected Obstetric Population in Late Pregnancy: a Multicenter Randomized Controlled Trial Unknown status NCT02907242
14 The Telomere System in Cord Blood and in the Placenta in High Risk Pregnancies Unknown status NCT01384136
15 Ultrasound Monitoring of Fetuses With Vascular Intra-uterine Growth Restriction (IUGR) Using the Isthmus Systolic Index (ISI): Feasibility, Comparison to Normal Fetuses and Association With Perinatal Mortality Unknown status NCT02813525
16 Variability in Middle Cerebral Artery Doppler Measurements in Uncomplicated Term Pregnancies. Unknown status NCT02968017
17 A Prospective, Randomized Multicenter Trial of Amnioreduction Vs Selective Fetoscopic Laser Photocoagulation for the Treatment of Severe Twin-Twin Transfusion Syndrome Unknown status NCT00345852
18 First-trimester Study of the Morphometric Characteristics of the Placenta to Assess the Risk of Preeclampsia and Intrauterine Growth Restriction in Singleton Pregnancies Unknown status NCT02879942
19 Frequency of Performing Umbilical Artery Doppler in the Third Trimester in High Risk Pregnancy A Randomized Controlled Trial Unknown status NCT03584763
20 Effect of Delayed Cord Clamping in Preterm Neonates With Placental Insufficiency Completed NCT03731546
21 Alkaline Phosphatase Level in Pregnancy and Its Association With Birth Weight Completed NCT03187938
22 Placental Insufficiency Screening During First Trimester by a Combination of Uterine Artery Dopppler, Maternal PlGF and sFLT-1 in Hight Risk Population Completed NCT01348711
23 Screening for Placental Insufficiency by a Combination of Second Trimester Uterine Artery Doppler and Maternal Serum Leptin and Lipids Completed NCT00465634
24 Promoting Awareness Fetal Movements and Focussing Interventions Reduce Fetal Mortality Stillbirth, a Stepped Wedge Cluster Randomised Trial. Completed NCT01777022
25 Intraumbilical Amino Acids and Glucose Supplementation Via Subcutaneously Implanted Port System by Severe IUGR Human Fetuses Completed NCT02596594
26 Comparative Study of Plasma Free DNA and Nucleosome Concentrations: Pathological Versus Normal Pregnancies Completed NCT01736826
27 Doppler Echocardiography Assessment of Cardiac Sparing Effect in Fetal Hypoxia Completed NCT03146507
28 Correlation Between Perineuraxial Anesthesia Fluid Resuscitation in Cesarean Section and Infant Neurobehaviors Completed NCT00987701 Ringer's Lactate;Six percent hydroxyethyl starch
29 The Evaluation of UTERO - Placental 3D Doppler Examination Potential Interest for Pre- Eclampsia Screening During Pregnancy. Observational Study in 100 Women at High Risk for Pre- Eclampsia and 70 Low Risk Women. Completed NCT00930397
30 Splanchnic Oxygenation and Perfusion Response to Enteral Feeds in Preterm Infants With Abnormal Antenatal Doppler: Pattern Assessment and Correlation With Feeding Intolerance Completed NCT02971566
31 Are Renal Artery Doppler Indices Different Between Monochorionic Diamniotic Twins With Twin-twin Transfusion Syndrome and Monochorionic Diamniotic Twins Without Twin-twin Transfusion Syndrome? Completed NCT03449823
32 Protocol for Testing the Efficiency of a Device Meant to Relieve Labour Pain Completed NCT00426725
33 Walking and Dietary Modification for Women With Consecutive Early Miscarriages: a Randomized Study Completed NCT03023137
34 Evaluation of Metabolic Acid-base Abnormalities in Pre-eclamptic Women Applying the Stewart-Fencl Approach Completed NCT02164370
35 Placental Insufficiency Microcirculation Quantification by Ultrafast Doppler: an Observational Prospective Study Recruiting NCT03860103
36 Impact of Umbilical Cord Milking in Preterm Neonates With Placental Insufficiency Recruiting NCT03731611
37 MRI Assessment of Placental Health Recruiting NCT02297724
38 The PREPPeD Study: "PREdelivery Placental Biomarkers- Pregnancy and Delivery Outcome" Recruiting NCT03100084
39 Prevalence of Antiphospholipid Antibodies Among Women With Preeclampsia Recruiting NCT02699437
40 Imaging Innovations for Placental Assessment in Response to Environmental Pollution Recruiting NCT02786420
41 Effect of L-Arginine on Intrauterine Growth Restriction Fetuses Measured by Birth Weight: Randomized Controlled Trial Recruiting NCT03321292 L-arginine 1000 mg and Acetylesalicylic acid75mg;acetylsalicylic acid 75 mg
42 Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation Recruiting NCT04093986
43 Preeclampsia Ratio (sFlt-1/PlGF) Evaluation for Clinical and Obstetrical Guidance Recruiting NCT03289611
44 The Lupus prEGnAnCY Cohort: An International Prospective Cohort of Lupus Pregnancies Recruiting NCT03746028
45 Reference Ranges for Placental Perfusion Using Magnetic Resonance Imaging (MRI)PLACENTIMAGE Active, not recruiting NCT01092949
46 Impact of Antioxidant Juice Intake on Brain Injury and Placental Pathology in Infants With Intrauterine Growth Restriction (IUGR) Active, not recruiting NCT04394910
47 Study of the Fetoplacental BOLD Effect in Pregnant Women Using Functional MRI Active, not recruiting NCT02238301
48 Oxygen for Category II Intrauterine Fetal Resuscitation: A Randomized, Noninferiority Trial Active, not recruiting NCT02741284 Room air;10L Oxygen by nonrebreather mask
49 LUMIERE on the PLACENTA : A Study on the Added Value of MRI Not yet recruiting NCT04166448
50 Effect of Maternal Iron Deficiency Anemia on Fetal Hemodynamics and Neonatal Outcome Not yet recruiting NCT04016922

Search NIH Clinical Center for Placental Insufficiency

Cochrane evidence based reviews: placental insufficiency

Sources

Genetic Tests for Placental Insufficiency

About this section
Sources

Anatomical Context for Placental Insufficiency

About this section

MalaCards organs/tissues related to Placental Insufficiency:

40
Placenta, Heart, Brain, Testes, Lung, Fetal Brain, Skeletal Muscle
Sources

Publications for Placental Insufficiency

About this section

Articles related to Placental Insufficiency:

(show top 50) (show all 1808)
# Title Authors PMID Year
1
Reduced maternal serum concentrations of angiopoietin-2 in the first trimester precede intrauterine growth restriction associated with placental insufficiency. 54 61
17949380 2007
2
The relationship between transplacental O2 diffusion and placental expression of PlGF, VEGF and their receptors in a placental insufficiency model of fetal growth restriction. 61 54
12740423 2003
3
Altered placental development and intrauterine growth restriction in IGF binding protein-1 transgenic mice. 61 54
12163461 2002
4
Placental expression of VEGF, PlGF and their receptors in a model of placental insufficiency-intrauterine growth restriction (PI-IUGR). 54 61
11945079 2002
5
Hypoxia regulates insulin-like growth factor-binding protein 1 in human fetal hepatocytes in primary culture: suggestive molecular mechanisms for in utero fetal growth restriction caused by uteroplacental insufficiency. 61 54
11397868 2001
6
Chronic hypoxemia: effects on developing nitrergic and dopaminergic amacrine cells. 61 54
10359329 1999
7
[The importance of determining trophoblastic beta 1-glycoprotein (TBG) for the early diagnosis and prognosis of placental insufficiency in pregnant women with habitual abortion]. 54 61
1814220 1991
8
Placental vascular tree characterization based on ex-vivo MRI with a potential application for placental insufficiency assessment. 61
32560856 2020
9
Baboon placental heparin-binding epidermal growth factor-like growth factor. 61
32272450 2020
10
Extreme elevations of alkaline phosphatase in pregnancy: A case report. 61
32461917 2020
11
Lower oxygen consumption and Complex I activity in mitochondria isolated from skeletal muscle of fetal sheep with intrauterine growth restriction. 61
32396498 2020
12
Stillbirth in women with diabetes: a retrospective analysis of fetal autopsy reports. 61
32567445 2020
13
Adverse perinatal outcome and placental abnormalities in pregnancies with major fetal congenital heart defects: a retrospective case-control study. 61
32557693 2020
14
Transcription factor AP2A affects sFLT1 expression and decidualization in decidual stromal cells: Implications to preeclampsia pathology. 61
32535226 2020
15
Fetal growth and fetoplacental circulation in pregnancies following bariatric surgery: a prospective study. 61
31955489 2020
16
Metabolic reprogramming by Zika virus provokes inflammation in human placenta. 61
32528049 2020
17
Impact of Saharan Dust on Severe Small for Gestational Births in the Caribbean. 61
32285767 2020
18
Does Fetal Pulmonary Venous Flow Impedance Increase in Pregnancies With Placental Insufficiency-Related Oligohydramnios in the Third Trimester? 61
31705722 2020
19
Maternal iron nutriture modulates placental development in a rat model of fetal alcohol spectrum disorder. 61
31734307 2020
20
Circulating mRNAs are differentially expressed in pregnancies with severe placental insufficiency and at high risk of stillbirth. 61
32438913 2020
21
Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction. 61
32415092 2020
22
[Splanchnic oximetry in small for gestational age neonates in relation to prenatal doppler study]. 61
31350206 2020
23
Postnatal development of skeletal muscle in pigs with intrauterine growth restriction: morphofunctional phenotype and molecular mechanisms. 61
31997379 2020
24
Anti-phospholipid antibodies and reproductive failures. 61
32347616 2020
25
Risk factors for perinatal arterial ischaemic stroke: a large case-control study. 61
31489622 2020
26
Pregnancy loss due to amnionitis in anglo-arabian mare-Case report. 61
31916285 2020
27
Oxygen and pulmonary vasodilation: The role of oxidative and nitrosative stress. 61
31983672 2020
28
Reduced Na+ K+ -ATPase activity may reduce amino acid uptake in intrauterine growth restricted fetal sheep muscle despite unchanged ex vivo amino acid transporter activity. 61
31909825 2020
29
An audit of oral administration of Angusta® (misoprostol) 25 µg for induction of labor in 976 consecutive women with a singleton pregnancy in a university hospital in Denmark. 61
32311758 2020
30
Deletion of hypoxia-responsive microRNA-210 results in a sex-specific decrease in nephron number. 61
32141129 2020
31
Physiological development of the equine fetus during late gestation. 61
31721295 2020
32
Conflicting Effects of Fetal Growth Restriction on Blood Pressure Between Human and Rat Offspring: A Meta-Analysis. 61
31983304 2020
33
Predictors of perinatal outcome in early-onset fetal growth restriction: A study from an emerging economy country. 61
31674030 2020
34
Inflammasomes-A Molecular Link for Altered Immunoregulation and Inflammation Mediated Vascular Dysfunction in Preeclampsia. 61
32093005 2020
35
Maternal plasma proteomics in a rat model of pregnancy complications reveals immune and pro-coagulant gene pathway activation. 61
31677200 2020
36
Heparin therapy in placental insufficiency: Systematic review and meta-analysis. 61
31519033 2020
37
Placental abnormalities differ in small for gestational age neonates in relation to their prenatal sonographic abdominal circumference measurements. 61
32106737 2020
38
The requirement of SUMO2/3 for SENP2 mediated extraembryonic and embryonic development. 61
31625212 2020
39
Circulating Delta-like homolog 1 (DLK1) at 36 weeks is correlated with birthweight and is of placental origin. 61
32174303 2020
40
Complex, coordinated and highly regulated changes in placental signaling and nutrient transport capacity in IUGR. 61
30684642 2020
41
Histological villous maturation in placentas of complicated pregnancies. 61
31985030 2020
42
The association between isolated oligohydramnios at term and placental pathology in correlation with pregnancy outcomes. 61
32056549 2020
43
Fetal cardiac remodeling and dysfunction is associated with both preeclampsia and fetal growth restriction. 61
31336074 2020
44
In vitro fertilization is associated with the onset and progression of preeclampsia. 61
31675490 2020
45
Neuronal vulnerability to fetal hypoxia-reoxygenation injury and motor deficit development relies on regional brain tetrahydrobiopterin levels. 61
31926630 2020
46
The Cerebral Hemodynamic Response to Pain in Preterm Infants With Fetal Growth Restriction. 61
32537447 2020
47
Placentae for Low Birth Weight Piglets Are Vulnerable to Oxidative Stress, Mitochondrial Dysfunction, and Impaired Angiogenesis. 61
32566107 2020
48
Cumulative Antenatal Risk and Kindergarten Readiness in Preterm-Born Preschoolers. 61
31418097 2020
49
Postmortem examination protocol and systematic re-evaluation reduce the proportion of unexplained stillbirths. 61
31990664 2020
50
Understanding Fetal Hemodynamics Using Cardiovascular Magnetic Resonance Imaging. 61
32062652 2020
Sources

Variations for Placental Insufficiency

About this section
Sources

Expression for Placental Insufficiency

About this section
Search GEO for disease gene expression data for Placental Insufficiency.
Sources

Pathways for Placental Insufficiency

About this section

Pathways related to Placental Insufficiency according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.82 VEGFA TEK PGF KDR IL6 HIF1A
2
PEDF Induced Signaling 63
Show member pathways
 13.66 TEK SOCS3 LEP KDR IL6 FLT1
3
TGF-Beta Pathway 63
Show member pathways
 13.47 VEGFA TEK SOCS3 PGF KDR IL6
4
Akt Signaling 63
Show member pathways
 13.4 TEK PGF KDR IL6 FLT1 CXCL8
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.34 VEGFA TEK SOCS3 IL6 HIF1A CXCL8
6
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 13.3 VEGFA TEK SERPINC1 FGR F3 F2
7
PAK Pathway 63
Show member pathways
 13.28 TEK PGF KDR IL6 FLT1 CXCL8
8
p70S6K Signaling 63
Show member pathways
 13.03 PGF KDR IL6 HIF1A FLT1 F2
9
PI3K-Akt signaling pathway 36
Show member pathways
 12.96 VEGFA TEK PGF KDR IL6 FLT1
10
Pathways in cancer 36
12.83 VEGFA PGF IL6 HIF1A F2 CXCL8
11
MAPK signaling pathway 36 1
12.77 VEGFA TEK PGF KDR FLT1 ANGPT2
12
Ras signaling pathway 36
Show member pathways
 12.74 VEGFA TEK PGF KDR FLT1 ANGPT2
13
Immune response IL-23 signaling pathway 22
Show member pathways
 12.6 TEK SOCS3 IL6 F2 ANGPT2 ANGPT1
14
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.37 TEK PGF KDR IL6 FLT1
15
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.29 SOCS3 PGF KDR IL6 FLT1 CXCL8
16
Cell surface interactions at the vascular wall 65
Show member pathways
 12.21 TEK F2 ANGPT2 ANGPT1
17
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.19 VEGFA TH IL6 HIF1A CXCL8
18
Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers 64
12.07 VEGFA KDR IL6 AFP
19
Adipogenesis 1
12.06 SOCS3 LEP IL6 HIF1A
20
Tyrosine Kinases / Adaptors 4
12.02 TEK SOCS3 KDR FLT1 FGR ANGPT2
21
Interleukin-4 and 13 signaling 65
11.99 VEGFA SOCS3 IL6 HIF1A CXCL8
22
AGE-RAGE signaling pathway in diabetic complications 36
11.91 VEGFA IL6 F3 CXCL8
23
Signaling events mediated by VEGFR1 and VEGFR2 1
Show member pathways
 11.82 VEGFA PGF KDR HIF1A FLT1
24
Glucocorticoid receptor regulatory network 1
11.77 IL6 CXCL8 AFP
25
Rheumatoid arthritis 36
11.7 VEGFA TEK IL6 FLT1 CXCL8 ANGPT1
26
HIF-1-alpha transcription factor network 1
11.66 VEGFA LEP HIF1A
27
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.64 VEGFA IL6 CXCL8
28
ATF-2 transcription factor network 1
11.62 TH SOCS3 IL6 CXCL8
29
Hepatitis C and Hepatocellular Carcinoma 1
11.58 VEGFA IL6 HIF1A CXCL8
30
Angiogenesis (CST) 4
11.58 TEK KDR HIF1A FLT1 F3 ANGPT2
31
HIF-1 signaling pathway 36
11.54 VEGFA TEK IL6 HIF1A FLT1 ANGPT2
32
Signaling events mediated by PTP1B 1
11.53 SOCS3 LEP FGR
33
Vemurafenib Pathway, Pharmacodynamics 60
11.46 VEGFA KDR FLT1
34
Photodynamic therapy-induced HIF-1 survival signaling 1
11.38 VEGFA HIF1A ANGPT2 ANGPT1
35
HIF-2-alpha transcription factor network 1
11.34 VEGFA KDR FLT1
36
Development_Leptin signaling via JAK/STAT and MAPK cascades 22
Show member pathways
 11.26 VEGFA SOCS3 LEP HIF1A
37
Glypican 1 network 1
11.15 VEGFA SERPINC1 FLT1 FGR
38
G-protein signaling_Rap2B regulation pathway 22
10.91 TEK PGF KDR IL6 FLT1 CXCL8
39
VEGF binds to VEGFR leading to receptor dimerization 65
Show member pathways
 10.83 VEGFA PGF KDR FLT1
40
miR-148a/miR-31/FIH1/HIF1andalpha;-Notch signaling in glioblastoma 1
10.63 VEGFA HIF1A
41
Angiogenesis (WikiPathways) 1
10.48 VEGFA TEK KDR HIF1A FLT1 ANGPT1
Sources

GO Terms for Placental Insufficiency

About this section

Cellular components related to Placental Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.77 VEGFA SERPINC1 PGF PAPPA LEP IL6
2 collagen-containing extracellular matrix GO:0062023 9.55 SERPINC1 F3 F2 ANGPT2 ANGPT1
3 extracellular region GO:0005576 9.53 VEGFA TEK SERPINC1 PGF PAPPA LEP

Biological processes related to Placental Insufficiency according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.24 VEGFA TEK PGF KDR FLT1 F2
2 cell differentiation GO:0030154 10.21 VEGFA PGF KDR HIF1A FLT1 FGR
3 positive regulation of gene expression GO:0010628 10.11 VEGFA IL6 HIF1A F3 ANGPT1
4 positive regulation of cell proliferation GO:0008284 10.11 VEGFA PGF MIR520A LEP KDR IL6
5 post-translational protein modification GO:0043687 10.06 SOCS3 SERPINC1 IL6 HIF1A AFP
6 negative regulation of apoptotic process GO:0043066 10.06 VEGFA TEK SOCS3 LEP KDR IL6
7 positive regulation of cell migration GO:0030335 10.03 VEGFA KDR FLT1 FGR F3
8 cytokine-mediated signaling pathway GO:0019221 10.03 VEGFA SOCS3 IL6 HIF1A F3 CXCL8
9 cellular protein metabolic process GO:0044267 10.02 SERPINC1 PAPPA IL6 F2 AFP
10 leukocyte migration GO:0050900 10 TEK F2 ANGPT2 ANGPT1
11 positive regulation of protein kinase B signaling GO:0051897 9.99 TEK LEP F3 ANGPT1
12 protein autophosphorylation GO:0046777 9.99 TEK KDR FLT1 FGR
13 regulation of cell shape GO:0008360 9.98 VEGFA KDR FGR F2
14 peptidyl-tyrosine phosphorylation GO:0018108 9.96 TEK KDR FLT1 FGR
15 positive regulation of protein phosphorylation GO:0001934 9.95 VEGFA TEK PGF LEP KDR F2
16 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.93 TEK KDR FLT1 FGR ANGPT1
17 positive regulation of MAPK cascade GO:0043410 9.92 TEK LEP KDR IL6 FLT1
18 response to hypoxia GO:0001666 9.91 VEGFA TH TEK PGF LEP HIF1A
19 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.9 VEGFA SOCS3 LEP IL6
20 positive regulation of kinase activity GO:0033674 9.89 TEK KDR FLT1
21 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.88 VEGFA PGF KDR FLT1
22 positive regulation of endothelial cell migration GO:0010595 9.88 VEGFA TEK KDR ANGPT1
23 hemostasis GO:0007599 9.87 SERPINC1 F3 F2
24 positive chemotaxis GO:0050918 9.86 VEGFA PGF ANGPT1
25 response to activity GO:0014823 9.85 TH LEP ANGPT2
26 lactation GO:0007595 9.85 VEGFA SERPINC1 HIF1A
27 positive regulation of blood vessel endothelial cell migration GO:0043536 9.85 VEGFA KDR HIF1A ANGPT1
28 negative regulation of endothelial cell apoptotic process GO:2000352 9.83 TEK KDR ANGPT1
29 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.83 VEGFA KDR FLT1
30 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.83 TEK FLT1 FGR
31 positive regulation of JAK-STAT cascade GO:0046427 9.82 LEP IL6 F2
32 blood vessel morphogenesis GO:0048514 9.82 HIF1A FLT1 ANGPT2
33 positive regulation of focal adhesion assembly GO:0051894 9.8 VEGFA TEK KDR
34 positive regulation of endothelial cell proliferation GO:0001938 9.8 VEGFA TEK PGF KDR HIF1A F3
35 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.8 TEK LEP KDR FLT1 FGR F2
36 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.79 VEGFA HIF1A FLT1
37 induction of positive chemotaxis GO:0050930 9.77 VEGFA PGF CXCL8
38 positive regulation of positive chemotaxis GO:0050927 9.74 VEGFA KDR F3
39 vascular endothelial growth factor signaling pathway GO:0038084 9.73 VEGFA PGF KDR FLT1
40 sexual reproduction GO:0019953 9.72 LEP AFP
41 negative regulation of lipid storage GO:0010888 9.71 LEP IL6
42 hyaloid vascular plexus regression GO:1990384 9.71 TH FLT1
43 vascular wound healing GO:0061042 9.71 VEGFA KDR
44 regulation of endothelial cell proliferation GO:0001936 9.71 LEP ANGPT1
45 ovulation from ovarian follicle GO:0001542 9.7 LEP AFP
46 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.7 VEGFA HIF1A
47 positive regulation of mast cell chemotaxis GO:0060754 9.69 VEGFA PGF
48 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.68 VEGFA KDR
49 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.68 VEGFA KDR
50 glomerulus vasculature development GO:0072012 9.67 TEK ANGPT2 ANGPT1

Molecular functions related to Placental Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.8 LEP FGR F2 ANGPT2 ANGPT1
2 heparin binding GO:0008201 9.56 VEGFA SERPINC1 PGF F2
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.54 TEK KDR FLT1
4 vascular endothelial growth factor binding GO:0038085 9.46 KDR FLT1
5 vascular endothelial growth factor-activated receptor activity GO:0005021 9.43 KDR FLT1
6 growth factor binding GO:0019838 9.33 TEK KDR FLT1
7 vascular endothelial growth factor receptor binding GO:0005172 9.32 VEGFA PGF
8 growth factor activity GO:0008083 9.26 VEGFA PGF IL6 F2
9 protein tyrosine kinase activity GO:0004713 8.92 TEK KDR FLT1 FGR
Sources

Sources for Placental Insufficiency

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....